Search research articles
Contact Us
Filters
Showing results (431-440 of 509) with videos related to
Page
of 51
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2023
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Muller, Angelina Legros, et al.
Blood Advances
|
February 26, 2025
Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France
Camille Bigenwald, Damien Roos-Weil, Arnaud Pagès, et al.
Gynecologic Oncology
|
October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
Antonio González-Martín, Christophe Desauw, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 5, 2025
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement - OSAMA Study)
Domenico Ferraioli, Fulvio Borella, Marie Meurer, et al.
The Lancet. Oncology
|
November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
Cancer
|
March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Lorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 31, 2020
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)
Astrid Lièvre, Anthony Turpin, Isabelle Ray-Coquard, et al.
JAMA Oncology
|
October 23, 2018
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial
Gerald Falchook, Robert L Coleman, Andrzej Roszak, et al.
Page
of 51
Search research articles
Search
Showing results (431-440 of 509) with videos related to
Sort By:
Page
of 51
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2023
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Muller, Angelina Legros, et al.
Blood Advances
|
February 26, 2025
Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France
Camille Bigenwald, Damien Roos-Weil, Arnaud Pagès, et al.
Gynecologic Oncology
|
October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
Antonio González-Martín, Christophe Desauw, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 5, 2025
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement - OSAMA Study)
Domenico Ferraioli, Fulvio Borella, Marie Meurer, et al.
The Lancet. Oncology
|
November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
Cancer
|
March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Lorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 31, 2020
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)
Astrid Lièvre, Anthony Turpin, Isabelle Ray-Coquard, et al.
JAMA Oncology
|
October 23, 2018
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial
Gerald Falchook, Robert L Coleman, Andrzej Roszak, et al.
Page
of 51